An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment
Yıl: 2019 Cilt: 3 Sayı: 1 Sayfa Aralığı: 22 - 27 Metin Dili: İngilizce DOI: 10.14744/ejmo.2018.0020 İndeks Tarihi: 21-04-2020
An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment
Öz: Objectives: We aimed to investigate the distribution of immunoreactivities of vascular endothelial growth factor(VEGF), endothelial nitric oxide synthase (eNOS), and inducible NOS (iNOS) on breast cancer cells in response to treatment with boron derivatives.Methods: We initially analyzed the cytotoxic effect and IC50 value of boron by MTT assay. For the evaluation of theangiogenesis, expression level of antibodies was detected to following boron derivatives such as boric acid, boronpenta (BP), and T-Boron (DPD) in the absence of boron treatment using the indirect immunohistochemical method. Theevaluation of these staining was done using the H-scoring system.Results: It was found that immunoreactivities of VEGF, eNOS, and iNOS increased on control compared to those of thecells of MDA-MB231 human breast cancer cell line. Following boron derivatives treatment, it was observed that theywere inhibited the VEGF/NOS labeling in MDA-MB-231 breast cancer cells.Conclusion: The present data suggest that BP, especially DPD, inhibits the angiogenesis of breast cancer cells throughVEGF pathway. From this point, these boron derivatives may provide a novel therapeutic approach for breast cancertreatment.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Yen WC, Prudente RY, Lamph WW. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat 2004;88:141–8.
- 2. Giovannini M, Aldrighetti D, Zucchinelli P, Belli C, Villa E. Antiangiogenic strategies in breast cancer management. Crit Rev Oncol Hematol 2010;76:13–35.
- 3. Scorei R, Ciubar R, Ciofrangeanu CM, Mitran V, Cimpean A, Iordachescu D, et al. Comparative effects of boric acid and calcium fructoborate on breast cancer cells. Biol Trace Elem Res 2008;122:197–205.
- 4. Pizzorno L. Nothing boring about boron. Integr Med (Encini- tas) 2015;14:35–48.
- 5. Barranco WT, Eckhert CD. Boric acid inhibits human prostate cancer cell proliferation. Cancer Lett 2004;216:21–9.
- 6. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013;123:3190–200.
- 7. Ribatti D, Djonov V. Intussusceptive microvascular growth in tumors. Cancer Lett 2012;316:126–31.
- 8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.
- 9. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794–814.
- 10. Ramanathan R, Olex AL, Dozmorov M, Bear HD, Fernandez LJ, Takabe K, et al. Angiopoietin pathway gene expression associated with poor breast cancer survival. Breast Cancer Res Treat 2017;162:191–8.
- 11. Chen J, Sun X, Shao R, Xu Y, Gao J, Liang W, et al. VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer. Int J Nanomedicine 2017;12:6075–88.
- 12. Saberi-Karimian M, Katsiki N, Caraglia M, Boccellino M, Majeed M, Sahebkar A, et al. Vascular endothelial growth factor: An important molecular target of curcumin. Crit Rev Food Sci Nutr 2017;1–14. doi: 10.1080/10408398.2017.1366892. [Epub ahead of print].
- 13. Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010;21:1436–41.
- 14. Eroğlu A, Ersöz C, Karasoy D, Sak S. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis. Adv Clin Exp Med 2017;26:245–9.
- 15. Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013;34:503–12.
- 16. Lala PK, Orucevic A. Role of nitric oxide in tumor progression: Lessons from experimental tumors. Cancer Metastasis Rev 1998;17:91–106.
- 17. Thomas DD, Wink DA. NOS2 as an emergent player in progression of cancer. Antioxid Redox Signal 2017;26:963–5.
- 18. Flaherty RL, Owen M, Fagan-Murphy A, Intabli H, Healy D, Patel A, et al. Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer. Breast Cancer Res 2017;19:35.
- 19. Uluer ET, Aydemir I, Inan S, Ozbilgin K, Vatansever HS. Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway. Acta Histochem 2012;114:641–6.
- 20. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR, et al. Tetrazolium-based assays for cellular viability: A critical examination of selected parameters affecting formazan production. Cancer Res 1991;51:2515–20.
- 21. Korkmaz M, Erson AE, Sapmaz A. Investigation of Possible Effects of Different Boron Concentrations on the Growth of Breast Cancer Cells. Turkey: Project No. BOREN-2007-G0150; 2008.
- 22. Nielsen FH. Update on human health effects of boron. J Trace Elem Med Biol 2014;28:383–7.
- 23. Tepedelen BE, Korkmaz M, Tatlisumak E, Uluer ET, Ölmez E, Değerli İ, et al. A study on the anticarcinogenic effects of calcium fructoborate. Biol Trace Elem Res 2017;178:210–7.
- 24. McAuley EM, Bradke TA, Plopper GE. Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration. Cell Adh Migr 2011;5:382–6.
- 25. Bradke TM, Hall C, Carper SW, Plopper GE. Phenylboronic acid selectively inhibits human prostate and breast cancer cell migration and decreases viability. Cell Adh Migr 2008;2:153–60.
- 26. Doğan A, Demirci S, Apdik H, Bayrak OF, Gulluoglu S, Tuysuz EC, et al. A new hope for obesity management: Boron inhibits adipogenesis in progenitor cells through the wnt/β-catenin pathway. Metabolism 2017;69:130–42.
- 27. Barranco WT, Eckhert CD. Cellular changes in boric acid-treated DU-145 prostate cancer cells. Br J Cancer 2006;94:884–90.
- 28. Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, et al. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Res 2015;17:25.
- 29. Walsh EM, Keane MM, Wink DA, Callagy G, Glynn SA. Review of triple negative breast cancer and the impact of inducible nitric oxide synthase on tumor biology and patient outcomes. Crit Rev Oncog 2016;21:333–51.
- 30. Ranganathan S, Krishnan A, Sivasithambaram ND. Significance of twist and iNOS expression in human breast carcinoma. Mol Cell Biochem 2016;412:41–7.
- 31. Kafousi M, Vrekoussis T, Tsentelierou E, Pavlakis K, Navrozoglou I, Dousias V, et al. Immunohistochemical study of the angiogenetic network of VEGF, HIF1α, VEGFR-2 and endothelial nitric oxide synthase (eNOS) in human breast cancer. Pathol Oncol Res 2012;18:33–41.
- 32. Loibl S, Strank C, von Minckwitz G, Sinn HP, Buck A, Solbach C, et al. Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. Breast 2005;14:230–5.
- 33. Loibl S, Bratengeier J, Farines V, von Minckwitz G, Spänkuch B, Schini-Kerth V, et al. Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS. Pathol Res Pract 2006;202:1–7.
- 34. Smoum R, Rubinstein A, Dembitsky VM, Srebnik M. Boron containing compounds as protease inhibitors. Chem Rev 2012;112:4156–220.
- 35. Whitley BR, Palmieri D, Twerdi CD, Church FC. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 2004;296:151–62.
- 36. Karimi M, Babaahmadi-Rezaei H, Mohammadzadeh G, Ghaffari MA. Effect of silibinin on maspin and ERα gene expression in MCF-7 human breast cancer cell line. Iran J Pathol 2017;12:135–43.
| APA | şimşek f, Inan S, Korkmaz M (2019). An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. , 22 - 27. 10.14744/ejmo.2018.0020 |
| Chicago | şimşek fatma,Inan Sevinc,Korkmaz Mehmet An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. (2019): 22 - 27. 10.14744/ejmo.2018.0020 |
| MLA | şimşek fatma,Inan Sevinc,Korkmaz Mehmet An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. , 2019, ss.22 - 27. 10.14744/ejmo.2018.0020 |
| AMA | şimşek f,Inan S,Korkmaz M An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. . 2019; 22 - 27. 10.14744/ejmo.2018.0020 |
| Vancouver | şimşek f,Inan S,Korkmaz M An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. . 2019; 22 - 27. 10.14744/ejmo.2018.0020 |
| IEEE | şimşek f,Inan S,Korkmaz M "An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment." , ss.22 - 27, 2019. 10.14744/ejmo.2018.0020 |
| ISNAD | şimşek, fatma vd. "An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment". (2019), 22-27. https://doi.org/10.14744/ejmo.2018.0020 |
| APA | şimşek f, Inan S, Korkmaz M (2019). An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. Eurasian Journal of Medicine and Oncology, 3(1), 22 - 27. 10.14744/ejmo.2018.0020 |
| Chicago | şimşek fatma,Inan Sevinc,Korkmaz Mehmet An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. Eurasian Journal of Medicine and Oncology 3, no.1 (2019): 22 - 27. 10.14744/ejmo.2018.0020 |
| MLA | şimşek fatma,Inan Sevinc,Korkmaz Mehmet An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. Eurasian Journal of Medicine and Oncology, vol.3, no.1, 2019, ss.22 - 27. 10.14744/ejmo.2018.0020 |
| AMA | şimşek f,Inan S,Korkmaz M An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. Eurasian Journal of Medicine and Oncology. 2019; 3(1): 22 - 27. 10.14744/ejmo.2018.0020 |
| Vancouver | şimşek f,Inan S,Korkmaz M An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. Eurasian Journal of Medicine and Oncology. 2019; 3(1): 22 - 27. 10.14744/ejmo.2018.0020 |
| IEEE | şimşek f,Inan S,Korkmaz M "An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment." Eurasian Journal of Medicine and Oncology, 3, ss.22 - 27, 2019. 10.14744/ejmo.2018.0020 |
| ISNAD | şimşek, fatma vd. "An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment". Eurasian Journal of Medicine and Oncology 3/1 (2019), 22-27. https://doi.org/10.14744/ejmo.2018.0020 |
